VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
Top Cited Papers
- 1 February 2006
- journal article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 290 (2) , H560-H576
- https://doi.org/10.1152/ajpheart.00133.2005
Abstract
Unlike during development, blood vessels in the adult are generally thought not to require VEGF for normal function. However, VEGF is a survival factor for many tumor vessels, and there are clues that some normal blood vessels may also depend on VEGF. In this study, we sought to identify which, if any, vascular beds in adult mice depend on VEGF for survival. Mice were treated with a small-molecule VEGF receptor (VEGFR) tyrosine kinase inhibitor or soluble VEGFRs for 1–3 wk. Blood vessels were assessed using immunohistochemistry or scanning or transmission electron microscopy. In a study of 17 normal organs after VEGF inhibition, we found significant capillary regression in pancreatic islets, thyroid, adrenal cortex, pituitary, choroid plexus, small-intestinal villi, and epididymal adipose tissue. The amount of regression was dose dependent and varied from organ to organ, with a maximum of 68% in thyroid, but was less in normal organs than in tumors in RIP-Tag2-transgenic mice or in Lewis lung carcinoma. VEGF-dependent capillaries were fenestrated, expressed high levels of both VEGFR-2 and VEGFR-3, and had normal pericyte coverage. Surviving capillaries in affected organs had fewer fenestrations and less VEGFR expression. All mice appeared healthy, but distinct physiological changes, including more efficient blood glucose handling, accompanied some regimens of VEGF inhibition. Strikingly, most capillaries in the thyroid grew back within 2 wk after cessation of treatment for 1 wk. Our findings of VEGF dependency of normal fenestrated capillaries and rapid regrowth after regression demonstrate the plasticity of the adult microvasculature.Keywords
This publication has 69 references indexed in Scilit:
- Genentech discloses safety concerns over AvastinNature Biotechnology, 2004
- Anti-Vascular Endothelial Growth Factor Monoclonals in Non-Small Cell Lung CancerClinical Cancer Research, 2004
- Circulating Angiogenic Factors and the Risk of PreeclampsiaNew England Journal of Medicine, 2004
- Antiobesity and antidiabetic effects of brain-derived neurotrophic factor in rodent models of leptin resistanceInternational Journal of Obesity, 2003
- Prevention of Thecal Angiogenesis, Antral Follicular Growth, and Ovulation in the Primate by Treatment with Vascular Endothelial Growth Factor Trap R1R2Endocrinology, 2002
- GIF biology and fat metabolismLife Sciences, 1999
- Vascular Endothelial Growth Factor Induces Endothelial Fenestrations In VitroThe Journal of cell biology, 1998
- Abnormal blood vessel development and lethality in embryos lacking a single VEGF alleleNature, 1996
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- Transendothelial transport (transcytosis) of iron—transferrin complex in the bone marrowJournal of Ultrastructure Research, 1984